Literature DB >> 14620298

The role of prostate specific antigen in screening and management of clinically localized prostate cancer.

Khurshid Guru1, Ashutosh Tewari, Ashok K Hemal, John Wei, Javid Javidan, James Peabody, Mani Menon.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2003        PMID： 14620298     DOI： 10.1023/a:1025978512921

Source DB:  PubMed          Journal:  Int Urol Nephrol        ISSN： 0301-1623            Impact factor:   2.370


× No keyword cloud information.
  61 in total

1.  Use of the percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicenter clinical trial.

Authors:  W J Catalona; A W Partin; K M Slawin; M K Brawer; R C Flanigan; A Patel; J P Richie; J B deKernion; P C Walsh; P T Scardino; P H Lange; E N Subong; R E Parson; G H Gasior; K G Loveland; P C Southwick
Journal:  JAMA       Date:  1998-05-20       Impact factor: 56.272

2.  Highly sensitive automated chemiluminometric assay for measuring free human glandular kallikrein-2.

Authors:  G G Klee; M K Goodmanson; S J Jacobsen; C Y Young; J A Finlay; H G Rittenhouse; R L Wolfert; D J Tindall
Journal:  Clin Chem       Date:  1999-06       Impact factor: 8.327

3.  Interval after prostate specific antigen testing and subsequent risk of incurable prostate cancer.

Authors:  S L Yao; G Lu-Yao
Journal:  J Urol       Date:  2001-09       Impact factor: 7.450

4.  Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis.

Authors:  A W Partin; W J Catalona; J A Finlay; C Darte; D J Tindall; C Y Young; G G Klee; D W Chan; H G Rittenhouse; R L Wolfert; D L Woodrum
Journal:  Urology       Date:  1999-11       Impact factor: 2.649

5.  Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging.

Authors:  W J Catalona; P C Southwick; K M Slawin; A W Partin; M K Brawer; R C Flanigan; A Patel; J P Richie; P C Walsh; P T Scardino; P H Lange; G H Gasior; K G Loveland; K R Bray
Journal:  Urology       Date:  2000-08-01       Impact factor: 2.649

6.  The effect of high grade prostatic intraepithelial neoplasia on serum total and percentage of free prostate specific antigen levels.

Authors:  C G Ramos; G F Carvahal; D E Mager; B Haberer; W J Catalona
Journal:  J Urol       Date:  1999-11       Impact factor: 7.450

7.  Treatment with finasteride preserves usefulness of prostate-specific antigen in the detection of prostate cancer: results of a randomized, double-blind, placebo-controlled clinical trial. PLESS Study Group. Proscar Long-term Efficacy and Safety Study.

Authors:  G L Andriole; H A Guess; J I Epstein; H Wise; D Kadmon; E D Crawford; P Hudson; C L Jackson; N A Romas; L Patterson; T J Cook; J Waldstreicher
Journal:  Urology       Date:  1998-08       Impact factor: 2.649

8.  Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men.

Authors:  William J Catalona; Jerome P Richie; Frederick R Ahmann; M'Liss A Hudson; Peter T Scardino; Robert C Flanigan; Jean B DeKernion; Timothy L Ratliff; Louis R Kavoussi; Bruce L Dalkin; W Bedford Waters; Michael T MacFarlane; Paula C Southwick
Journal:  J Urol       Date:  1994-05       Impact factor: 7.450

9.  Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening.

Authors:  W J Catalona; D S Smith; R L Wolfert; T J Wang; H G Rittenhouse; T L Ratliff; R B Nadler
Journal:  JAMA       Date:  1995-10-18       Impact factor: 56.272

10.  A prospective evaluation of plasma prostate-specific antigen for detection of prostatic cancer.

Authors:  P H Gann; C H Hennekens; M J Stampfer
Journal:  JAMA       Date:  1995-01-25       Impact factor: 56.272
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.